MedTrace Logo

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

NCT01994382 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2022-04-05

Study results available
· View outcomes & findings →

Summary

This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin lymphoma.

Conditions

  • Follicular Lymphoma (FL/Indolent NHL)
  • Aggressive NHL (a NHL)
  • Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
  • T-cell Lymphoma (PTCL and CTCL)
  • B-cell Non Hodgkin Lymphoma (NHL)

Interventions

DRUG

Cerdulatinib

Oral capsule

BIOLOGICAL

Rituximab

IV infusion

Sponsors & Collaborators

  • Portola Pharmaceuticals

    collaborator INDUSTRY

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Portola Study Director · Portola Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-30
Primary Completion
2020-12-15
Completion
2020-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01994382 on ClinicalTrials.gov